

**From:** dph.immunizations@ct.gov <noreply@everbridge.net>  
**Sent:** Wednesday, November 13, 2024 8:20 AM  
**Subject:** ACIP Meeting Recommended Changes to Vaccine Schedule



[Please click here to acknowledge receipt of this message](#)

November 13, 2024

*This communication is being sent to all key contacts at provider organizations enrolled in the pediatric CT Vaccine Program (CVP) and CT Vaccine for Adult (CVFA) Program. Please feel free to share it with others in your organization who may benefit from the update. Note that all our communications are archived on our [website](#).*

The Advisory Committee on Immunization Practices (ACIP) meeting took place October 23–24 and the following recommendations were approved by majority vote and added to the [immunization schedule](#).

### **Pneumococcal Conjugate Vaccine**

ACIP recommends a single dose of pneumococcal conjugate vaccine (PCV) for all PCV-naïve **adults aged ≥50 years**.

### **Meningococcal Group B Vaccine**

- ACIP voted to recommend GSK’s meningococcal Group B vaccine (Bexsero) be administered as a **2-dose series at 0 and 6 months when given to healthy adolescents and young adults aged 16–23 years** for the prevention of serogroup B meningococcal disease.
- ACIP voted to recommend GSK’s meningococcal Group B vaccine (Bexsero) be administered as a **3-dose series at 0, 1-2, and 6 months when given to persons aged ≥10 years at increased risk for serogroup B meningococcal disease** (i.e., persons with anatomic or functional asplenia, complement component deficiencies, or complement inhibitor use; microbiologists routinely exposed to *N. meningitidis* isolates; and persons at increased risk during an outbreak).

## COVID-19 Vaccine

In addition to the previously recommended 2024–2025 vaccination:

- ACIP recommends **a second dose\*** of 2024– 2025 COVID-19 vaccine for adults ages 65 years and older.
- ACIP recommends **a second dose\*** of 2024– 2025 COVID-19 vaccine for people ages 6 months-64 years who are moderately or severely immunocompromised.
- ACIP recommends **additional doses (i.e., 3 or more doses)** of 2024– 2025 COVID-19 vaccine for people ages 6 months and older who are moderately or severely immunocompromised under **shared clinical decision-making**.
- People ages 12 years and older who are initiating vaccination with Novavax COVID-19 vaccine and receive a first dose of Novavax should complete the 2-dose initial vaccination series with Novavax vaccine. If more than 8 weeks have elapsed since receipt of the first dose of Novavax, any 2024– 2025 COVID-19 vaccine may be administered.

\* The second dose is recommended 6 months after the first dose of 2024–2025 Formula COVID-19 vaccine, with a minimum interval of 2 months.

As always, thank you for your ongoing efforts and support of vaccination.

**For the CT DPH Immunization Program, visit: [Contact Us](#)**

*If you would like to subscribe to receive these communications, please complete [this form](#). If you would like to unsubscribe from receiving these communications, please complete [this form](#).*